Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

Reither, Klaus; Katsoulis, Lynn; Beattie, Trevor; Gardiner, Nicolene; Lenz, Nicole; Said, Khadija; Mfinanga, Elirehema; Pohl, Christian; Fielding, Katherine L; Jeffery, Hannah; +10 more... Kagina, Benjamin M; Hughes, Elisabeth J; Scriba, Thomas J; Hanekom, Willem A; Hoff, Søren T; Bang, Peter; Kromann, Ingrid; Daubenberger, Claudia; Andersen, Peter; Churchyard, Gavin J; (2014) Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. PloS one, 9 (12). e114602-. ISSN 1932-6203 DOI: https://doi.org/10.1371/journal.pone.0114602

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1371/journal.pone.0114602

Abstract

Share

Download

Filename: pone.0114602.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar